ERBB2 and invasive breast carcinoma: We sought to determine the frequency and importance of DARPP-32 expression in two large independent cohorts of early stage invasive breast cancer patients, including an additional cohort of HER2 positive breast cancer patients treated with trastuzumab to examine if DARPP-32 was associated with patient survival.